Novavax Inc. (NVAX)
6.07
0.06 (1.00%)
At close: Apr 22, 2025, 11:52 AM
1.00% (1D)
| Bid | 6.06 |
| Market Cap | 975.52M |
| Revenue (ttm) | 682.16M |
| Net Income (ttm) | -187.5M |
| EPS (ttm) | -1.23 |
| PE Ratio (ttm) | -4.93 |
| Forward PE | 10.91 |
| Analyst | Hold |
| Ask | 6.07 |
| Volume | 1,080,620 |
| Avg. Volume (20D) | 4,786,629 |
| Open | 6.04 |
| Previous Close | 6.01 |
| Day's Range | 6.06 - 6.22 |
| 52-Week Range | 3.90 - 23.86 |
| Beta | 3.14 |
About NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 5, 1995
Employees 952
Stock Exchange NASDAQ
Ticker Symbol NVAX
Website https://www.novavax.com
Analyst Forecast
According to 6 analyst ratings, the average rating for NVAX stock is "Hold." The 12-month stock price forecast is $18.5, which is an increase of 205.03% from the latest price.
Stock ForecastsNext Earnings Release
Novavax Inc. is scheduled to release its earnings on May 9, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago
-2.97%
Shares of vaccine stocks are trading lower after C...
Unlock content with
Pro Subscription
1 week ago
-19.56%
Novavax shares are trading lower following comments by RFK Jr. on the company's COVID-19 vaccine in an interview.
